Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: Results of a Russian multicenter study

Паровичникова, Е Н; Кузьмина, Л А; Mendeleeva, Larisa; Klyasova, Galina; Troitskaya, Vera V.; Sokolov, A N; Akhmerzaeva, Zalina; Кравченко, С К; Грибанова, Е О; Звонков, Е Е; Bondarenko, Sergey N.; Baranova, Olga; Рыльцова, Т. В.; Гаврилова, Л В; Zinina, Elena; Pristupa, Aleksander; Kaporskaya, Tatyana S; Минаева, Н В; Samoilova, Olga; Konstantinova, T. S.; Лапин, В. А.; Kaplanov, Kamil; Kryuchkova, I. V.; Низамутдинова, А. С.; Климович, А В; Borisenkova, Elena; Москов, В. И.; Гапонова, Т. В.; Обухова, Т В; Galtseva, Irina; Русинов, М А; Kulikov, Sergey; Vg, Savchenko

doi:10.17116/terarkh201587715-25

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poor outcomes in certain subgroups of PTCL after CHT have led to the trend of consolidation with HDT/ASCT [82–85•]. In a study by Reimer et al (2009), ASCT used as first line therapy in patients with PTCL showed that estimated 3-year OS and PFS were 48% and 36%, respectively.…”

Section: Introductionmentioning

confidence: 99%

A Review of Autologous Stem Cell Transplantation in Lymphoma

Zahid

Akbar

Amaraneni

et al. 2017

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Purpose of review Chemotherapy remains the first line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin Lymphoma (HL) recur after initial therapy. We want to explore the role of high dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. Recent findings There is some utility of upfront consolidation for high risk/high grade B cell lymphoma, mantle cell lymphoma and T cell lymphoma but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Summary Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high dose consolidation or in the maintenance setting.

show abstract

Section: Introductionmentioning

confidence: 99%

A Review of Autologous Stem Cell Transplantation in Lymphoma

Zahid

Akbar

Amaraneni

et al. 2017

Curr Hematol Malig Rep

View full text Add to dashboard Cite

show abstract

“…Additionally, patients with diseases sensitive to chemotherapy who achieved a CR with ASCT demonstrated an 84% 4-year OS compared to 44% for those with partial responses [56]. However, poor outcomes in some PTCL subgroups following CHT have led to a trend of consolidating HDC followed by ASCT [57][58][59][60]. In a study carried out by Reimer et al (2009), patients having PTCL who underwent ASCT as first-line therapies had an assessed 3-year OS of 48% and PFS of 36%.…”

Section: Asct In Peripheral T-cell Lymphoma (Ptcl)mentioning

confidence: 99%

Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis

Alnasser,

Alharbi,

Almutairy

et al. 2023

Cells

View full text Add to dashboard Cite

Human body cells are stem cell (SC) derivatives originating from bone marrow. Their special characteristics include their capacity to support the formation and self-repair of the cells. Cancer cells multiply uncontrollably and invade healthy tissues, making stem cell transplants a viable option for cancer patients undergoing high-dose chemotherapy (HDC). When chemotherapy is used at very high doses to eradicate all cancer cells from aggressive tumors, blood-forming cells and leukocytes are either completely or partially destroyed. Autologous stem cell transplantation (ASCT) is necessary for patients in those circumstances. The patients who undergo autologous transplants receive their own stem cells (SCs). The transplanted stem cells first come into contact with the bone marrow and then undergo engraftment, before differentiating into blood cells. ASCT is one of the most significant and innovative strategies for treating diseases. Here we focus on the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, and AL amyloidosis, using ASCT. This review provides a comprehensive picture of the effectiveness and the safety of ASCT as a therapeutic approach for these diseases, based on the currently available evidence.

show abstract

Russian multicenter clinical trials in acute leukemias

Паровичникова¹,

Vg²

2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The paper describes the results of 15 consecutive Russian clinical trials in the treatment of different types of acute leukemias, conducted by Russian cooperative group within the last 27-years and included more than 25 hundred patients. It was shown that the 5-years overall survival in AML younger than 60 years patients improved from 20 to 33%, in ALL - from 38 to 65%, in APL - from 0 to 95%. The cooperative work resulted in balanced clinical recommendations and protocols, reproducible in regional hospitals. Though till now there is a big difference in the long term outcome in acute leukemias patients treated in coordinating or regional centers mostly due to much higher early death rate: 7.5-9.5% vs 18-25%. This parameter should be used as criteria of the total efficacy of hematological service in each region of Russia. It became possible within the last years to integrate the minimal residual disease monitoring into clinical trials thus providing a clue parameter for choosing the further therapy - allogeneic stem cell transplantation. Non - chemotherapeutic approach with arsenic trioxide and all - trans retinoid acid had dramatically changed the toxicity and duration of treatment with very high efficacy. The Russian cooperative group was the first that started to include pregnant women with acute leukemias into clinical trials. This prospective and prolonged experience has shown that pregnancy in acute myeloid leukemia is an extremely poor prognostic factor, but it does not influence the outcome in acute lymphoblastic leukemia.

show abstract

Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: Results of a Russian multicenter study

Cited by 3 publications

References 15 publications

A Review of Autologous Stem Cell Transplantation in Lymphoma

A Review of Autologous Stem Cell Transplantation in Lymphoma

Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis

Russian multicenter clinical trials in acute leukemias

Contact Info

Product

Resources

About